Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2023 08:00 ET | Source: Longeveron

Longeveron Announces Pricing for Rights Offering and Expected Calendar

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
August 11, 2023 07:30 ET | Source: Longeveron

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial Anticipated by October 2023 Company...
August 11, 2023 07:00 ET | Source: Longeveron

Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-B™ in the Treatment of HLHS to be held Wednesday,...
August 07, 2023 08:00 ET | Source: Longeveron

Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023

MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 20, 2023 08:00 ET | Source: Longeveron

Longeveron Appoints Lisa Locklear as Chief Financial Officer

MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 11, 2023 08:00 ET | Source: Longeveron

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

MIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 10, 2023 08:00 ET | Source: Longeveron

Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
June 27, 2023 18:07 ET | Source: Longeveron

Longeveron Files Registration Statement for Rights Offering

MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
June 13, 2023 08:30 ET | Source: Longeveron

Longeveron Welcomes Three New Prominent Board Members

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of Stockholders MIAMI, June 13, 2023 (GLOBE NEWSWIRE) --...
May 12, 2023 08:00 ET | Source: Longeveron

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2...